(Q30838717)

27 June 2017

title

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

27 June 2017

0 references

0 references

author name string

Mark Sanford

series ordinal

1

1 reference

27 June 2017

publication date

1 August 2014

1 reference

27 June 2017

1 reference

27 June 2017

volume

74

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

1411-1433

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0264-y

27 June 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

New perspectives in the natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Age at disability milestones in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Drugs in development for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Clinical pharmacokinetics of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

An update on sphingosine-1-phosphate and other sphingolipid mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod treatment in multiple sclerosis leads to increased macular volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Population pharmacokinetics of fingolimod phosphate in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

FTY720 pharmacokinetics in mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Mu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Early tolerability and safety of fingolimod in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Guidelines for the management of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0264-Y

Ethnic sensitivity study of fingolimod in white and Asian subjects

21 January 2018

1 reference

12 December 2020

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands

1 reference

12 December 2020

Diagnosis and management of multiple sclerosis.

1 reference

12 December 2020

Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions

1 reference

12 December 2020

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

1 reference

12 December 2020

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis

1 reference

12 December 2020

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

1 reference

12 December 2020

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip

1 reference

12 December 2020

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

1 reference

12 December 2020

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

1 reference

12 December 2020

Alemtuzumab for multiple sclerosis: who and when to treat?

1 reference

12 December 2020

10.1007/S40265-014-0264-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

27 June 2017

1034998631

0 references

1 reference